{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:43:43Z","timestamp":1775195023579,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["MySMIS 107124: Funding Contract 2\/Axa 1\/31.07.2017\/ 107124 SMI"],"award-info":[{"award-number":["MySMIS 107124: Funding Contract 2\/Axa 1\/31.07.2017\/ 107124 SMI"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministery of Research and Innovation, CNCS - UEFISCDI","award":["PN-III-P4-ID-PCE-2016-0908"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2016-0908"]}]},{"name":"Ministery of Research and Innovation, CNCS - UEFISCDI","award":["contract number 167\/2017"],"award-info":[{"award-number":["contract number 167\/2017"]}]},{"name":"Ministery of Research and Innovation, CNCS - UEFISCDI","award":["within PNCDI III"],"award-info":[{"award-number":["within PNCDI III"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11255-019-02170-w","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T20:13:52Z","timestamp":1558556032000},"page":"1173-1189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-1588","authenticated-orcid":false,"given":"Cristiana","family":"Vlad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Burlacu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Florea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Artene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Badarau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Covic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Ureche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragos","family":"Scripcariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Foia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"issue":"9","key":"2170_CR1","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/ndt\/gfg276","volume":"18","author":"DS Parsons","year":"2003","unstructured":"Parsons DS, Reaveley DA, Pavitt DV, Misra M, Brown EA (2003) Lipoprotein(a) levels in those with high molecular weight apo(a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol Dial Transpl 18(9):1848\u20131853","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"2170_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.krcp.2013.10.002","volume":"32","author":"KA Park","year":"2013","unstructured":"Park KA, Jo HM, Han JS, Kim MJ, do Kwun H, Park MY, Choi SJ, Kim JK, Hwang SD (2013) Features of atherosclerosis in hemodialysis patients. Kidney Res Clin Pract 32(4):177\u2013182. https:\/\/doi.org\/10.1016\/j.krcp.2013.10.002","journal-title":"Kidney Res Clin Pract"},{"issue":"2","key":"2170_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000337082","volume":"2","author":"MB Nusair","year":"2012","unstructured":"Nusair MB, Rajpurohit N, Alpert MA (2012) Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. Cardioren Med 2(2):117\u2013124","journal-title":"Cardioren Med"},{"issue":"4","key":"2170_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","volume":"91","author":"RO Mathew","year":"2017","unstructured":"Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, Asif A (2017) Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int 91(4):797\u2013807. https:\/\/doi.org\/10.1016\/j.kint.2016.09.049","journal-title":"Kidney Int"},{"issue":"3","key":"2170_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ahj.2011.12.002","volume":"163","author":"GR Shroff","year":"2012","unstructured":"Shroff GR, Frederick PD, Herzog CA (2012) Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System\/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 163(3):399\u2013406. https:\/\/doi.org\/10.1016\/j.ahj.2011.12.002","journal-title":"Am Heart J"},{"issue":"6","key":"2170_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s11255-013-0407-1","volume":"45","author":"S Olechnowicz-Tietz","year":"2013","unstructured":"Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J (2013) The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol 45(6):1605\u20131612. https:\/\/doi.org\/10.1007\/s11255-013-0407-1","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"2170_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneph.2010.143","volume":"6","author":"TB Drueke","year":"2010","unstructured":"Drueke TB, Massy ZA (2010) Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 6(12):723\u2013735. https:\/\/doi.org\/10.1038\/nrneph.2010.143","journal-title":"Nat Rev Nephrol"},{"key":"2170_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/IJNRD.S101808","volume":"10","author":"I Mikolasevic","year":"2017","unstructured":"Mikolasevic I, Zutelija M, Mavrinac V, Orlic L (2017) Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 10:35\u201345. https:\/\/doi.org\/10.2147\/IJNRD.S101808","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"2170_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrneph.2010.157","volume":"7","author":"V Kon","year":"2011","unstructured":"Kon V, Linton MF, Fazio S (2011) Atherosclerosis in chronic kidney disease: the role of macrophages. Nat Rev Nephrol 7(1):45\u201354. https:\/\/doi.org\/10.1038\/nrneph.2010.157","journal-title":"Nat Rev Nephrol"},{"key":"2170_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cellsig.2018.12.001","volume":"55","author":"P Shrestha","year":"2019","unstructured":"Shrestha P, van de Sluis B, Dullaart RPF, van den Born J (2019) Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell Signal 55:53\u201364. https:\/\/doi.org\/10.1016\/j.cellsig.2018.12.001","journal-title":"Cell Signal"},{"issue":"2","key":"2170_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000077293","volume":"24","author":"E Emanuele","year":"2004","unstructured":"Emanuele E, Lusignani LS, Peros E, Montagna G, D\u2019Angelo A, Montagna L, Geroldi D (2004) Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients. Am J Nephrol 24(2):221\u2013229. https:\/\/doi.org\/10.1159\/000077293","journal-title":"Am J Nephrol"},{"issue":"1","key":"2170_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND (2016) Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 90(1):41\u201352. https:\/\/doi.org\/10.1016\/j.kint.2016.02.026","journal-title":"Kidney Int"},{"issue":"1","key":"2170_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","volume":"27","author":"F Kronenberg","year":"1996","unstructured":"Kronenberg F, Utermann G, Dieplinger H (1996) Lipoprotein(a) in renal disease. Am J Kidney Dis 27(1):1\u201325","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2170_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0272-6386(03)00413-X","volume":"42","author":"JC Longenecker","year":"2003","unstructured":"Longenecker JC, Coresh J, Marcovina SM, Powe NR, Levey AS, Giaculli F, Fink NE, Klag MJ (2003) Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 42(1):108\u2013116","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2170_CR15","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/ndt\/gfv428","volume":"31","author":"B Kollerits","year":"2016","unstructured":"Kollerits B, Drechsler C, Krane V, Lamina C, Marz W, Dieplinger H, Ritz E, Wanner C, Kronenberg F, German D, Dialysis Study I (2016) Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrol Dial Transpl 31(11):1901\u20131908. https:\/\/doi.org\/10.1093\/ndt\/gfv428","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"2170_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","volume":"18","author":"F Kronenberg","year":"2014","unstructured":"Kronenberg F (2014) Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol 18(2):234\u2013237. https:\/\/doi.org\/10.1007\/s10157-013-0875-8","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"2170_CR17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","volume":"10","author":"F Kronenberg","year":"1999","unstructured":"Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol JASN 10(5):1027\u20131036","journal-title":"J Am Soc Nephrol JASN"},{"issue":"11","key":"2170_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1177\/039139880703001107","volume":"30","author":"GA Kaysen","year":"2007","unstructured":"Kaysen GA (2007) Hyperlipidemia in chronic kidney disease. Int J Artif Organs 30(11):987\u2013992","journal-title":"Int J Artif Organs"},{"issue":"6","key":"2170_CR19","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1681\/ASN.2004110922","volume":"16","author":"JC Longenecker","year":"2005","unstructured":"Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J (2005) High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol JASN 16(6):1794\u20131802. https:\/\/doi.org\/10.1681\/ASN.2004110922","journal-title":"J Am Soc Nephrol JASN"},{"issue":"39","key":"2170_CR20","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, Group ESCSD (2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999\u20133058. https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"issue":"22","key":"2170_CR21","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301(22):2331\u20132339. https:\/\/doi.org\/10.1001\/jama.2009.801","journal-title":"JAMA"},{"key":"2170_CR22","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.1046\/j.1523-1755.1999.07164.x","volume":"71","author":"H Ohashi","year":"1999","unstructured":"Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S (1999) Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl 71:S242\u2013S244","journal-title":"Kidney Int Suppl"},{"issue":"9","key":"2170_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","volume":"64","author":"P Willeit","year":"2014","unstructured":"Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S (2014) Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64(9):851\u2013860. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.061","journal-title":"J Am Coll Cardiol"},{"key":"2170_CR24","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1046\/j.1523-1755.1999.07167.x","volume":"71","author":"Y Koda","year":"1999","unstructured":"Koda Y, Nishi S, Suzuki M, Hirasawa Y (1999) Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 71:S251\u2013S253","journal-title":"Kidney Int Suppl"},{"issue":"1\u20132","key":"2170_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cca.2008.07.012","volume":"397","author":"JC Longenecker","year":"2008","unstructured":"Longenecker JC, Coresh J, Klag MJ, Powe NR, Fink NE, Marcovina SM (2008) Lipoprotein(a) level as a predictor of cardiovascular disease and small apolipoprotein(a) isoforms in dialysis patients: assay-related differences are important. Clin Chim Acta 397(1\u20132):36\u201341. https:\/\/doi.org\/10.1016\/j.cca.2008.07.012","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2170_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2796.2012.02585.x","volume":"272","author":"B Kollerits","year":"2012","unstructured":"Kollerits B, Krane V, Drechsler C, Lamina C, Marz W, Ritz E, Wanner C, Kronenberg F, German D, Dialysis Study I (2012) Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus\u2014a post hoc analysis of the 4D Study. J Intern Med 272(6):592\u2013600. https:\/\/doi.org\/10.1111\/j.1365-2796.2012.02585.x","journal-title":"J Intern Med"},{"issue":"2","key":"2170_CR27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","volume":"55","author":"J Zimmermann","year":"1999","unstructured":"Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55(2):648\u2013658. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00273.x","journal-title":"Kidney Int"},{"issue":"5","key":"2170_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1399-0004.1997.tb04357.x","volume":"52","author":"F Kronenberg","year":"1997","unstructured":"Kronenberg F, Trenkwalder E, Sturm W, Kathrein H, Konig P, Neyer U, Grochenig E, Utermann G, Dieplinger H (1997) LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients. Clin Genet 52(5):377\u2013386","journal-title":"Clin Genet"},{"issue":"5","key":"2170_CR29","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","volume":"55","author":"P Stenvinkel","year":"1999","unstructured":"Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T (1999) Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55(5):1899\u20131911. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00422.x","journal-title":"Kidney Int"},{"issue":"12","key":"2170_CR30","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.V8121889","volume":"8","author":"M Koch","year":"1997","unstructured":"Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F (1997) Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol JASN 8(12):1889\u20131898","journal-title":"J Am Soc Nephrol JASN"},{"issue":"3","key":"2170_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/nejmoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German D, Dialysis Study I (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238\u2013248. https:\/\/doi.org\/10.1056\/nejmoa043545","journal-title":"N Engl J Med"},{"issue":"14","key":"2170_CR32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/nejmoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395\u20131407. https:\/\/doi.org\/10.1056\/nejmoa0810177","journal-title":"N Engl J Med"},{"issue":"1","key":"2170_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2478\/jtim-2018-0005","volume":"6","author":"A Verdoodt","year":"2018","unstructured":"Verdoodt A, Honore PM, Jacobs R, De Waele E, Van Gorp V, De Regt J, Spapen HD (2018) Do statins induce or protect from acute kidney injury and chronic kidney disease: an update review in 2018. J Transl Intern Med 6(1):21\u201325. https:\/\/doi.org\/10.2478\/jtim-2018-0005","journal-title":"J Transl Intern Med"},{"issue":"1","key":"2170_CR34","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.21037\/jtd.2017.01.40","volume":"9","author":"K Kotani","year":"2017","unstructured":"Kotani K, Banach M (2017) Lipoprotein(a) and inhibitors of proprotein convertase subtilisin\/kexin type 9. J Thorac Dis 9(1):E78\u2013E82","journal-title":"J Thorac Dis"},{"key":"2170_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cca.2018.09.010","volume":"487","author":"M Castro Cabezas","year":"2018","unstructured":"Castro Cabezas M, Burggraaf B, Klop B (2018) Dyslipidemias in clinical practice. Clin Chim Acta 487:117\u2013125. https:\/\/doi.org\/10.1016\/j.cca.2018.09.010","journal-title":"Clin Chim Acta"},{"issue":"10057","key":"2170_CR36","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057):2239\u20132253. https:\/\/doi.org\/10.1016\/S0140-6736(16)31009-1","journal-title":"Lancet"},{"issue":"4","key":"2170_CR37","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jacl.2016.03.003","volume":"10","author":"JP Corsetti","year":"2016","unstructured":"Corsetti JP, Gansevoort RT, Bakker SJL, Dullaart RPF (2016) Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the prevention of renal and vascular end-stage disease study. J Clin Lipidol 10(4):842\u2013850. https:\/\/doi.org\/10.1016\/j.jacl.2016.03.003","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2170_CR38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1053\/ajkd.2000.17682","volume":"36","author":"G Guz","year":"2000","unstructured":"Guz G, Nurhan Ozdemir F, Sezer S, Isiklar I, Arat Z, Turan M, Haberal M (2000) Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 36(4):826\u2013836. https:\/\/doi.org\/10.1053\/ajkd.2000.17682","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2170_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/j.ajkd.2003.10.013","volume":"43","author":"E Liberopoulos","year":"2004","unstructured":"Liberopoulos E, Siamopoulos K, Elisaf M (2004) Apolipoprotein E and renal disease. Am J Kidney Dis 43(2):223\u2013233","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2170_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1525-139X.2006.00117.x","volume":"19","author":"J Liu","year":"2006","unstructured":"Liu J, Rosner MH (2006) Lipid abnormalities associated with end-stage renal disease. Semin Dial 19(1):32\u201340. https:\/\/doi.org\/10.1111\/j.1525-139X.2006.00117.x","journal-title":"Semin Dial"},{"issue":"6","key":"2170_CR41","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1161\/01.CIR.100.6.608","volume":"100","author":"E Ilveskoski","year":"1999","unstructured":"Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J, Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ (1999) Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 100(6):608\u2013613","journal-title":"Circulation"},{"key":"2170_CR42","doi-asserted-by":"publisher","first-page":"S245","DOI":"10.1046\/j.1523-1755.1999.07165.x","volume":"71","author":"T Imura","year":"1999","unstructured":"Imura T, Kimura H, Gejyo F (1999) Apolipoprotein E phenotypes in hemodialysis patients. Kidney Int Suppl 71:S245\u2013S247","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"2170_CR43","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.2215\/CJN.02560607","volume":"2","author":"BI Freedman","year":"2007","unstructured":"Freedman BI, Bostrom M, Daeihagh P, Bowden DW (2007) Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol CJASN 2(6):1306\u20131316. https:\/\/doi.org\/10.2215\/CJN.02560607","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"8","key":"2170_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.14740\/jocmr3046e","volume":"9","author":"Y Wang","year":"2017","unstructured":"Wang Y, Wang N, Lu Y, Yu Q, Zhou L, Xu Q (2017) Detection of apolipoprotein E gene polymorphism and blood lipid level in hemodialysis patients. J Clin Med Res 9(8):695\u2013700. https:\/\/doi.org\/10.14740\/jocmr3046e","journal-title":"J Clin Med Res"},{"issue":"1","key":"2170_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.atherosclerosis.2009.06.036","volume":"208","author":"K Winkler","year":"2010","unstructured":"Winkler K, Hoffmann MM, Krane V, Marz W, Drechsler C, Wanner C (2010) Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis 208(1):197\u2013202. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.06.036","journal-title":"Atherosclerosis"},{"issue":"4","key":"2170_CR46","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ndt\/12.4.691","volume":"12","author":"M Olmer","year":"1997","unstructured":"Olmer M, Renucci JE, Planells R, Bouchouareb D, Purgus R (1997) Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transpl 12(4):691\u2013693","journal-title":"Nephrol Dial Transpl"},{"key":"2170_CR47","first-page":"243","volume":"15","author":"KH Choi","year":"1999","unstructured":"Choi KH, Song HY, Shin SK, Noh H, Kang SW, Kim JH, Lee HY, Han DS (1999) Influence of apolipoprotein E genotype on lipid and lipoprotein levels in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial Conf Perit Dial 15:243\u2013246","journal-title":"Adv Perit Dial Conf Perit Dial"},{"issue":"4","key":"2170_CR48","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1681\/ASN.2006091006","volume":"18","author":"BC Kwan","year":"2007","unstructured":"Kwan BC, Kronenberg F, Beddhu S, Cheung AK (2007) Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol JASN 18(4):1246\u20131261. https:\/\/doi.org\/10.1681\/ASN.2006091006","journal-title":"J Am Soc Nephrol JASN"},{"issue":"2","key":"2170_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/gtmb.2014.0267","volume":"19","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhang L, Cao B (2015) The association between serum ApoE genetic polymorphism and serum lipid level in hemodialysis patients. Genet Test Mol Biomark 19(2):93\u201397. https:\/\/doi.org\/10.1089\/gtmb.2014.0267","journal-title":"Genet Test Mol Biomark"},{"issue":"5","key":"2170_CR50","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/jphp.12356","volume":"67","author":"K Wang","year":"2015","unstructured":"Wang K, Wang P, Qiao Y, Lu X, Wang X, Liu Z (2015) The effects of serum apolipoprotein E genetic variants and concentration on serum lipid parameters in haemodialysis patients. J Pharm Pharmacol 67(5):696\u2013702. https:\/\/doi.org\/10.1111\/jphp.12356","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"2170_CR51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000486846","volume":"46","author":"CZ Zheng","year":"2018","unstructured":"Zheng CZ, Qi XM, Shu YB, Bai YW, Wu YG (2018) Associations between apolipoprotein E gene polymorphisms and cardiovascular complications of uremic patients on maintenance hemodialysis. Blood Purif 46(1):48\u201355. https:\/\/doi.org\/10.1159\/000486846","journal-title":"Blood Purif"},{"issue":"9","key":"2170_CR52","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/ndt\/12.9.1916","volume":"12","author":"PS Lim","year":"1997","unstructured":"Lim PS, Liu CS, Hong CJ, Wei YH (1997) Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients. Nephrol Dial Transpl 12(9):1916\u20131920","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"2170_CR53","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.biopha.2011.04.003","volume":"65","author":"AD Dergunov","year":"2011","unstructured":"Dergunov AD (2011) Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. Biomed Pharmacother 65(8):597\u2013603. https:\/\/doi.org\/10.1016\/j.biopha.2011.04.003","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2170_CR54","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/mp.2013.194","volume":"19","author":"C Conejero-Goldberg","year":"2014","unstructured":"Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, Hyde TM, Kleinman JE, Herman MM, Chen S, Davies P, Goldberg TE (2014) APOE2 enhances neuroprotection against Alzheimer\u2019s disease through multiple molecular mechanisms. Mol Psychiatry 19(11):1243\u20131250. https:\/\/doi.org\/10.1038\/mp.2013.194","journal-title":"Mol Psychiatry"},{"issue":"4","key":"2170_CR55","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3233\/JAD150690","volume":"51","author":"SK Singhrao","year":"2016","unstructured":"Singhrao SK, Harding A, Chukkapalli S, Olsen I, Kesavalu L, Crean S (2016) Apolipoprotein E related co-morbidities and Alzheimer\u2019s disease. J Alzheimer\u2019s Dis JAD 51(4):935\u2013948. https:\/\/doi.org\/10.3233\/JAD150690","journal-title":"J Alzheimer\u2019s Dis JAD"},{"issue":"1","key":"2170_CR56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","volume":"17","author":"M Safieh","year":"2019","unstructured":"Safieh M, Korczyn AD, Michaelson DM (2019) ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease. BMC Med 17(1):64. https:\/\/doi.org\/10.1186\/s12916-019-1299-4","journal-title":"BMC Med"},{"key":"2170_CR57","first-page":"185","volume":"1","author":"D Kirmizis","year":"2007","unstructured":"Kirmizis D, Koutoupa E, Tsiandoulas A, Valtopoulou A, Niavis G, Markou P, Barboutis K (2007) Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomark Insights 1:185\u2013192","journal-title":"Biomark Insights"},{"issue":"1","key":"2170_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-018-0771-z","volume":"17","author":"X Zhan","year":"2018","unstructured":"Zhan X, Chen Y, Yan C, Liu S, Deng L, Yang Y, Qiu P, Pan D, Zeng B, Chen Q (2018) Apolipoprotein B\/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids Health Dis 17(1):117. https:\/\/doi.org\/10.1186\/s12944-018-0771-z","journal-title":"Lipids Health Dis"},{"key":"2170_CR59","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cca.2015.10.033","volume":"454","author":"I Ramasamy","year":"2016","unstructured":"Ramasamy I (2016) Update on the molecular biology of dyslipidemias. Clin Chim Acta 454:143\u2013185. https:\/\/doi.org\/10.1016\/j.cca.2015.10.033","journal-title":"Clin Chim Acta"},{"issue":"12","key":"2170_CR60","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C (2018) Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 14(12):727\u2013749. https:\/\/doi.org\/10.1038\/s41581-018-0072-9","journal-title":"Nat Rev Nephrol"},{"key":"2170_CR61","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1046\/j.1523-1755.63.s84.34.x","volume":"84","author":"BH Prinsen","year":"2003","unstructured":"Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ (2003) Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 84:S121\u2013S124. https:\/\/doi.org\/10.1046\/j.1523-1755.63.s84.34.x","journal-title":"Kidney Int Suppl"},{"key":"2170_CR62","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1038\/sj.ki.5001926","volume":"103","author":"SS Prichard","year":"2006","unstructured":"Prichard SS (2006) Management of hyperlipidemia in patients on peritoneal dialysis: current approaches. Kidney Int Suppl 103:S115\u2013S117. https:\/\/doi.org\/10.1038\/sj.ki.5001926","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"2170_CR63","first-page":"151","volume":"15","author":"S Bevc","year":"2006","unstructured":"Bevc S, Hojs R, Ekart R, Hojs-Fabjan T (2006) Atherosclerosis in hemodialysis patients: traditional and nontraditional risk factors. Acta dermatovenerologica Alpina, Pannonica, et Adriatica 15(4):151\u2013157","journal-title":"Acta dermatovenerologica Alpina, Pannonica, et Adriatica"},{"issue":"1","key":"2170_CR64","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11255-017-1737-1","volume":"50","author":"M Ye","year":"2018","unstructured":"Ye M, Liu Y, Wang H, Tian N, Li W, He W, Lin H, Fan R, Li C, Liu D, Yao F (2018) Serum apolipoprotein B is inversely associated with eccentric left ventricular hypertrophy in peritoneal dialysis patients. Int Urol Nephrol 50(1):155\u2013165. https:\/\/doi.org\/10.1007\/s11255-017-1737-1","journal-title":"Int Urol Nephrol"},{"key":"2170_CR65","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijcard.2018.03.077","volume":"261","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Kuwabara M, Johnson R, Bove M, Fogacci F, Rosticci M, Giovannini M, D\u2019Addato S, Borghi C, Brisighella Heart Study g (2018) LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: data from the Brisighella Heart Study cohort. Int J Cardiol 261:204\u2013208. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.077","journal-title":"Int J Cardiol"},{"issue":"5","key":"2170_CR66","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2215\/CJN.09830915","volume":"11","author":"Y Sato","year":"2016","unstructured":"Sato Y, Fujimoto S, Toida T, Nakagawa H, Yamashita Y, Iwakiri T, Fukuda A, Iwatsubo S (2016) Apoprotein B\/apoprotein A-1 ratio and mortality among prevalent dialysis patients. Clin J Am Soc Nephrol CJASN 11(5):840\u2013846. https:\/\/doi.org\/10.2215\/CJN.09830915","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"5","key":"2170_CR67","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1046\/j.1523-1755.2002.00319.x","volume":"61","author":"ND Vaziri","year":"2002","unstructured":"Vaziri ND, Liang K (2002) Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 61(5):1769\u20131775. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00319.x","journal-title":"Kidney Int"},{"issue":"1","key":"2170_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmacy6010010","volume":"6","author":"D Zodda","year":"2018","unstructured":"Zodda D, Giammona R, Schifilliti S (2018) Treatment strategy for dyslipidemia in cardiovascular disease prevention: focus on old and new drugs. Pharmacy 6(1):1. https:\/\/doi.org\/10.3390\/pharmacy6010010","journal-title":"Pharmacy"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02170-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T12:33:39Z","timestamp":1663504419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02170-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2170"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02170-w","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}